[Translation] Randomized, single-blind, placebo-controlled evaluation of the tolerability, safety and immunogenicity of different doses of therapeutic human papillomavirus type 16 recombinant adenovirus vector vaccine (Pulsicon®) in Chinese adult women (25-45 years old) Initial exploratory phase I clinical trial
主要目的:评价不同剂量人乳头瘤病毒16型重组腺病毒载体疫苗在持续感染人乳头瘤病毒16型成年女性(25-45周岁)中的安全性和耐受性。
次要目的:初步探索不同剂量人乳头瘤病毒16型重组腺病毒载体疫苗的免疫原性。
[Translation] Main objective: To evaluate the safety and tolerability of different doses of human papillomavirus 16 recombinant adenovirus vector vaccine in adult women (25-45 years old) persistently infected with human papillomavirus 16.
Secondary objective: To preliminarily explore the immunogenicity of different doses of human papillomavirus 16 recombinant adenovirus vector vaccine.